Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge

Still Company's Third-Biggest Seller

 
• By Kevin Grogan
  
shield
Novartis has successfully shielded Gilenya from generics • Source: Alamy

More from Neurological

More from Therapy Areas